CAMP4 Therapeutics
- Total Funding$30 M
OverviewSuggest Edit
CAMP4 Therapeutics is a biotechnology company. It offers Gene Circuitry Platform, an approach capable of mapping the transcriptional machinery and network of signaling pathways that control gene expression across cells in the human body.
| Type | Private | |
| Founded | 2016 | |
| HQ | Cambridge, MA, US | Map |
| Website | camp4tx.com |
Latest Updates
| Employees (est.) (Jun 2022) | 61 | (+2%) |
| Cybersecurity rating | A | More |
Key People/Management at CAMP4 Therapeutics
Josh Mandel-Brehm
President & Chief Executive Officer, Director
Jorge Conde
Director
David Bumcrot
Chief Scientific Officer
Michael Higgins
Diretor
Kelly Gold
Chief Business Officer, SVP Finance
Amir Nashat
Director
CAMP4 Therapeutics Office Locations
CAMP4 Therapeutics has an office in Cambridge
Cambridge, MA, US (HQ)
One Kendall Square, Binney St
CAMP4 Therapeutics Financials and Metrics
Summary Metrics
Founding Date | 2016 |
CAMP4 Therapeutics total Funding | $30 m |
CAMP4 Therapeutics latest funding size | $30 m |
Time since last funding | 4 years ago |
CAMP4 Therapeutics investors | Andreessen Horowitz, Polaris Partners, The Kraft Group |
CAMP4 Therapeutics's latest funding round in May 2018 was reported to be $30 m. In total, CAMP4 Therapeutics has raised $30 m
CAMP4 Therapeutics Cybersecurity Score
CAMP4 Therapeutics Online and Social Media Presence
CAMP4 Therapeutics's Trends
CAMP4 Therapeutics News and Updates
July 12, 2021
OPKO Health Licenses Oligonucleotide Therapeutics Platform to CAMP4 Therapeutics
MIAMI, July 12, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced it has entered into an exclusive worldwide agreement with privately held CAMP4 Therapeutics Corporation (CAMP4) for the development, manufacture and commercialization of therapeutics utilizing the AntagoNAT te…
CAMP4 Therapeutics Blogs
April 19, 2022
CAMP4 Therapeutics Promotes Kelly Gold to Chief Financial Officer
Finance and business development veteran and founding member of CAMP4 leadership team CAMBRIDGE, Mass., April 19, 2022 – CAMP4 Therapeutics, a biotechnology company harnessing the power of regulatory RNAs to upregulate genes and restore healthy expression, today announced that it has appointed Kelly…
March 14, 2022
CAMP4 Therapeutics Appoints Veteran Drug Developer Ann Barbier, M.D., Ph.D. as Chief Medical Officer
Al Sandrock, M.D., Ph.D. joins Scientific Advisory Board CAMBRIDGE, Mass., March 14, 2022 – CAMP4 Therapeutics, a biotechnology company harnessing the power of regulatory RNAs to upregulate genes and restore healthy expression, today announced that it has appointed Ann Barbier, M.D., Ph.D., as Chief…
December 03, 2021
CAMP4 Presents In Vivo Data Supporting Novel Therapeutic Strategy for Dravet Syndrome at American Epilepsy Society Annual Meeting
Upregulation of SCN1A gene expression by targeting regulatory RNAs Company to advance oligonucleotide development candidate for Dravet Syndrome; expected to file IND by YE 2022 CAMBRIDGE, Mass., December 3, 2021 – CAMP4 Therapeutics, a biotechnology company harnessing the power of RNA to restore hea…
September 27, 2021
CAMP4 Presents First Preclinical Data Demonstrating the Therapeutic Potential of its RNA Actuating Platform at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
Novel approach to upregulating gene expression by targeting regulatory RNAs Company to advance development candidate for urea cycle disorders; expected to enter clinical trials in 2023 CAMBRIDGE, Mass., September 27, 2021 – CAMP4 Therapeutics, a biotechnology company harnessing the power of RNA to r…
July 13, 2021
CAMP4 Therapeutics Expands Leadership and Board of Directors
Kelly Gold promoted to Chief Business Officer and SVP, Finance Michelle Gates appointed SVP, Chief People Officer Ravi Thadhani, M.D., M.P.H. named to board of directors CAMBRIDGE, Mass., July 13, 2021 – CAMP4 Therapeutics, a biotechnology company harnessing the power of RNA to restore healthy gen…
June 15, 2021
CAMP4 Raises $45 Million to Usher in a New Era of Programmable Therapeutics to Upregulate Genes
Proceeds to fuel expansion of RNA Actuating Platform™ designed to harness the power of regulatory RNA to restore healthy gene expression Company advancing preclinical pipeline initially focused on CNS and liver diseases; first IND expected in 2022 Funding led by 5AM Ventures and Northpond Ventures, …
CAMP4 Therapeutics Frequently Asked Questions
When was CAMP4 Therapeutics founded?
CAMP4 Therapeutics was founded in 2016.
Who are CAMP4 Therapeutics key executives?
CAMP4 Therapeutics's key executives are Josh Mandel-Brehm, Jorge Conde and David Bumcrot.
How many employees does CAMP4 Therapeutics have?
CAMP4 Therapeutics has 61 employees.
Who are CAMP4 Therapeutics competitors?
Competitors of CAMP4 Therapeutics include Oxford BioTherapeutics, MicrofluidX and Affinia Therapeutics.
Where is CAMP4 Therapeutics headquarters?
CAMP4 Therapeutics headquarters is located at One Kendall Square, Binney St, Cambridge.
Where are CAMP4 Therapeutics offices?
CAMP4 Therapeutics has an office in Cambridge.
How many offices does CAMP4 Therapeutics have?
CAMP4 Therapeutics has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies